Market Cap€13.9m

Last Close €0.64

Deinove is a biotechnology company that discovers, develops and produces high value-added compounds using its state-of-the-art bacterial strain selection, banking, fermentation and screening facilities. The most valuable compounds in the pipeline are novel antimicrobials, with lead asset DNV3837 in a Phase II trial.

More Deinove content >

Investment summary

Deinove is running an Phase II trial with its novel quinolonyl-oxazolidinone class antibiotic DNV3837 for moderate to severe Clostridium difficile infections. This is an open-label study being conducted in two parts across 15 centres in the US. An interim analysis by data and safety monitoring board is expected mid-2021 prior to commencement of the second part of the trial which will randomise 30 patients and assess efficacy endpoints. In March, Deinove reported it had been awarded a €500–800k grant by the French government to develop its Boost-ID project; it will use the proceeds to implement a high-throughput antimicrobial screening platform, anticipated to be operational by end-2021. In January, Deinove issued the 4th and 5th tranches of its convertible note programme with an aggregate value of €4.5m.

Y/E Dec
Revenue (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2018A 0.8 (9.4) (10.5) (61.25) N/A N/A
2019A 0.6 (10.8) (12.2) (58.75) N/A N/A
2020E N/A N/A N/A N/A N/A N/A
2021E N/A N/A N/A N/A N/A N/A
Industry outlook

Environmentalism will underpin growth in green chemistry and growing antimicrobial resistance to current antibiotics will demand the discovery of new antibiotic structures.

Last updated on 26/05/2021
Content on Deinove
Deinove – Phase II study with DNV3837 for C. diff starts
Healthcare | Update | 21 February 2020
Deinove – Steady progress on all fronts
Healthcare | Update | 16 October 2019
Deinove – Preparing for DNV3837 Phase II trial start
Healthcare | Update | 25 April 2019
View more
Register to receive research on Deinove as it is published
Share price graph
Balance sheet
Forecast net debt (€m) 14.7
Forecast gearing ratio (%) 164
Price performance
Actual (8.0) (22.0) (20.3)
Relative* (9.3) (29.8) (41.8)
52-week high/low €1.2/€0.5
*% relative to local index
Key management
Dr Charles Woler Chairman
Alexis Rideau CEO
Mario Alcaraz CFO